Month: January 2022

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Mowi ASA announces intention to launch voluntary offer for NTS ASA at NOK 110 per share 24 January 2022 – Mowi ASA is pleased to announce that it intends to launch an offer to acquire all of the shares of NTS ASA at NOK 110 per share, to be settled 50 % in cash and 50 % in shares issued in Mowi. Mowi has followed the NTS Group for several years and is impressed by how the employees, management team and owners have developed the NTS Group into one of the leading producers of Atlantic salmon in Norway and Iceland. From a strong foundation in Central Norway, the NTS Group has grown into a fully integrated...

Agreement to divest the FPSO BW Joko Tole BW Offshore has today signed an agreement for the sale of the FPSO BW Joko Tole to PT Bahari Inti Tanker and PT Cahaya Haluan Pasifik, both of which are Indonesian companies, in consortium with PT Buana Lintas Lautan Tbk, a company publicly listed in Indonesia. The consortium will continue to operate the FPSO under the lease contract with Kangean Energy Indonesia. The transaction is part of BW Offshore’s strategy to transition to floating energy infrastructure investments. The sale will free up over USD 50 million of liquidity, comprising of net sale proceeds of USD 42.5 million and the release of USD 9 million of working capital upon closing. There is no debt attached to the FPSO. The Company expects to book a loss from the transaction of around USD 23 million and a tax expense of approximately...

Top-line Data Expected in the Third Quarter of 2022 LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-2 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). Top-line data are expected in the third quarter of 2022. “Completing enrollment in the Phase 3 ENHANCE-2 trial with more than 800 subjects is an important accomplishment for Verona Pharma,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer. “We are pleased to achieve our recruitment targets during the ongoing global pandemic.” “We expect...

Ageas and Ping An: Transparency notification In accordance with the rules on financial transparency*, Ping An has notified Ageas on 21 January 2022 that, on 19 January 2022, its interest has fallen below the statutory threshold of 3% of the shares issued by Ageas. Its current shareholding stands at 0%. Reason for the notification Acquisition or disposal of voting securities or voting rightsDownward crossing of the lowest threshold Notification by A parent undertaking or a controlling person Persons subject to the notification requirementSee annex 1a Date on which the threshold is crossed 19 January 2022 Threshold that is crossed (in %) 3% Denominator 191,033,128 Notified details See annex 1 b Chain of controlled undertakings through which the holding is effectively held, if applicable The full chain of command can be found on https://www.ageas.com/investors/shareholders This...

Basel, Switzerland, January 24, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with cancer and infectious diseases, announced today that updated interim results from cohort 2 of the phase 2 study FIDES-01 (Fibroblast growth factor Inhibition with DErazantinib in Solid tumors) were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium 2022, held from January 20 to 22, in San Francisco, USA. Cohort 2 of FIDES-01 is assessing the safety and anti-tumor activity of Basilea’s orally administered fibroblast growth factor receptor (FGFR) inhibitor, derazantinib, in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA), a form of bile duct cancer, harboring FGFR2 mutations or amplifications.1 At...

January 24, 2022 Fourth-quarter highlightsGroup sales amounted to EUR 4.9 billion, with a 10% comparable sales decline Comparable order intake increased 4%, driven by double-digit growth in the Diagnosis & Treatment businesses Income from continuing operations amounted to EUR 139 million and included an impact of EUR 220 million related to the addition to the Respironics field action provision; income from continuing operations was EUR 508 million in Q4 2020 Adjusted EBITA of EUR 647 million, or 13.1% of sales, compared to EUR 995 million, or 19.0% of sales, in Q4 2020 Operating cash flow was EUR 720 million, resulting in a free cash flow of EUR 519 millionFull-year highlightsGroup sales amounted to EUR 17.2 billion, with high-single-digit comparable sales growth in the Diagnosis & Treatment and Personal Health businesses,...

WISeKey to Participate at the Blockchain Conference “Trends in the World of NFTs and Crypto” Presented by Maxim Group and Hosted by M-Vest on January 27 Geneva – January 24, 2022 – WISeKey International Holding Ltd. (“WISeKey,” SIX: WIHN / Nasdaq: WKEY), a leading global Semi-conductor, AI and IoT company, today announced that its CEO, Carlos Moreira is scheduled to participate in two panel discussions at the Blockchain Conference “Trends in the World of NFTs and Crypto” presented by Maxim Group LLC and hosted by M-Vest, on Thursday, January 27, starting at 12:00 noon ET (6:00 pm CET). Conference agenda and registration details can be found at https://m-vest.com/events/2022-blockchain-conference. Specifically, Mr. Moreira will participate in the following panel discussions:12:00 noon ET: Go to market strategies panel –...